Autoimmune hepatitis in children: An overview of the disease focusing on current therapies

Claudia Della Corte, Maria Rita Sartorelli, Carmen Donatella Sindoni, Elia Girolami, Luigi Giovannelli, Donatella Comparcola, Valerio Nobili

Research output: Contribution to journalArticle

Abstract

Autoimmune hepatitis (AIH) is an immune-mediated necroinflammatory disease of the liver characterized by elevation of IgG, presence of characteristic autoantibodies, and histological features of interface hepatitis. Two types of juvenile AIH have been recognized according to seropositivity for smooth muscle and/or antinuclear antibody (AIH type 1) or liver kidney microsomal antibody (AIH type 2). The exact pathogenesis of AIH is still unclear, but it is known that unidentified environmental factors, and occasionally drugs, might trigger disease in genetically susceptible individuals. The clinical spectrum of this disease is very wide, ranging from asymptomatic individuals with abnormal liver function to those with fulminant liver failure. The diagnosis is based on a combination of biochemical and histological parameters and on exclusion of other liver diseases. It is a relatively rare but devastating disease, which progresses rapidly unless immunosuppressive treatment is started promptly. Standard therapy consists of a combination of corticosteroids and azathioprine, which is efficacious in 80% of patients. Alternative therapies are increasingly being explored in patients who do not respond to standard treatment and/or have intolerable side-effects. The purpose of this paper is to review our current knowledge about AIH in children, evaluating mainly the therapeutic options for its treatment, considering also the newer immunosuppressant agents used in difficult-to-treat cases.

Original languageEnglish
Pages (from-to)739-746
Number of pages8
JournalEuropean Journal of Gastroenterology and Hepatology
Volume24
Issue number7
DOIs
Publication statusPublished - Jul 2012

Fingerprint

Autoimmune Hepatitis
Immunosuppressive Agents
Liver Diseases
Therapeutics
Acute Liver Failure
Liver
Antinuclear Antibodies
Azathioprine
Complementary Therapies
Rare Diseases
Autoantibodies
Hepatitis
Smooth Muscle
Adrenal Cortex Hormones
Immunoglobulin G
Kidney
Antibodies
Pharmaceutical Preparations

Keywords

  • autoimmune hepatitis
  • children
  • immunosuppression

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Autoimmune hepatitis in children : An overview of the disease focusing on current therapies. / Della Corte, Claudia; Sartorelli, Maria Rita; Sindoni, Carmen Donatella; Girolami, Elia; Giovannelli, Luigi; Comparcola, Donatella; Nobili, Valerio.

In: European Journal of Gastroenterology and Hepatology, Vol. 24, No. 7, 07.2012, p. 739-746.

Research output: Contribution to journalArticle

Della Corte, Claudia ; Sartorelli, Maria Rita ; Sindoni, Carmen Donatella ; Girolami, Elia ; Giovannelli, Luigi ; Comparcola, Donatella ; Nobili, Valerio. / Autoimmune hepatitis in children : An overview of the disease focusing on current therapies. In: European Journal of Gastroenterology and Hepatology. 2012 ; Vol. 24, No. 7. pp. 739-746.
@article{fe16f77c320a441fbd872c27b0c641c7,
title = "Autoimmune hepatitis in children: An overview of the disease focusing on current therapies",
abstract = "Autoimmune hepatitis (AIH) is an immune-mediated necroinflammatory disease of the liver characterized by elevation of IgG, presence of characteristic autoantibodies, and histological features of interface hepatitis. Two types of juvenile AIH have been recognized according to seropositivity for smooth muscle and/or antinuclear antibody (AIH type 1) or liver kidney microsomal antibody (AIH type 2). The exact pathogenesis of AIH is still unclear, but it is known that unidentified environmental factors, and occasionally drugs, might trigger disease in genetically susceptible individuals. The clinical spectrum of this disease is very wide, ranging from asymptomatic individuals with abnormal liver function to those with fulminant liver failure. The diagnosis is based on a combination of biochemical and histological parameters and on exclusion of other liver diseases. It is a relatively rare but devastating disease, which progresses rapidly unless immunosuppressive treatment is started promptly. Standard therapy consists of a combination of corticosteroids and azathioprine, which is efficacious in 80{\%} of patients. Alternative therapies are increasingly being explored in patients who do not respond to standard treatment and/or have intolerable side-effects. The purpose of this paper is to review our current knowledge about AIH in children, evaluating mainly the therapeutic options for its treatment, considering also the newer immunosuppressant agents used in difficult-to-treat cases.",
keywords = "autoimmune hepatitis, children, immunosuppression",
author = "{Della Corte}, Claudia and Sartorelli, {Maria Rita} and Sindoni, {Carmen Donatella} and Elia Girolami and Luigi Giovannelli and Donatella Comparcola and Valerio Nobili",
year = "2012",
month = "7",
doi = "10.1097/MEG.0b013e328353750c",
language = "English",
volume = "24",
pages = "739--746",
journal = "European Journal of Gastroenterology and Hepatology",
issn = "0954-691X",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Autoimmune hepatitis in children

T2 - An overview of the disease focusing on current therapies

AU - Della Corte, Claudia

AU - Sartorelli, Maria Rita

AU - Sindoni, Carmen Donatella

AU - Girolami, Elia

AU - Giovannelli, Luigi

AU - Comparcola, Donatella

AU - Nobili, Valerio

PY - 2012/7

Y1 - 2012/7

N2 - Autoimmune hepatitis (AIH) is an immune-mediated necroinflammatory disease of the liver characterized by elevation of IgG, presence of characteristic autoantibodies, and histological features of interface hepatitis. Two types of juvenile AIH have been recognized according to seropositivity for smooth muscle and/or antinuclear antibody (AIH type 1) or liver kidney microsomal antibody (AIH type 2). The exact pathogenesis of AIH is still unclear, but it is known that unidentified environmental factors, and occasionally drugs, might trigger disease in genetically susceptible individuals. The clinical spectrum of this disease is very wide, ranging from asymptomatic individuals with abnormal liver function to those with fulminant liver failure. The diagnosis is based on a combination of biochemical and histological parameters and on exclusion of other liver diseases. It is a relatively rare but devastating disease, which progresses rapidly unless immunosuppressive treatment is started promptly. Standard therapy consists of a combination of corticosteroids and azathioprine, which is efficacious in 80% of patients. Alternative therapies are increasingly being explored in patients who do not respond to standard treatment and/or have intolerable side-effects. The purpose of this paper is to review our current knowledge about AIH in children, evaluating mainly the therapeutic options for its treatment, considering also the newer immunosuppressant agents used in difficult-to-treat cases.

AB - Autoimmune hepatitis (AIH) is an immune-mediated necroinflammatory disease of the liver characterized by elevation of IgG, presence of characteristic autoantibodies, and histological features of interface hepatitis. Two types of juvenile AIH have been recognized according to seropositivity for smooth muscle and/or antinuclear antibody (AIH type 1) or liver kidney microsomal antibody (AIH type 2). The exact pathogenesis of AIH is still unclear, but it is known that unidentified environmental factors, and occasionally drugs, might trigger disease in genetically susceptible individuals. The clinical spectrum of this disease is very wide, ranging from asymptomatic individuals with abnormal liver function to those with fulminant liver failure. The diagnosis is based on a combination of biochemical and histological parameters and on exclusion of other liver diseases. It is a relatively rare but devastating disease, which progresses rapidly unless immunosuppressive treatment is started promptly. Standard therapy consists of a combination of corticosteroids and azathioprine, which is efficacious in 80% of patients. Alternative therapies are increasingly being explored in patients who do not respond to standard treatment and/or have intolerable side-effects. The purpose of this paper is to review our current knowledge about AIH in children, evaluating mainly the therapeutic options for its treatment, considering also the newer immunosuppressant agents used in difficult-to-treat cases.

KW - autoimmune hepatitis

KW - children

KW - immunosuppression

UR - http://www.scopus.com/inward/record.url?scp=84862172190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862172190&partnerID=8YFLogxK

U2 - 10.1097/MEG.0b013e328353750c

DO - 10.1097/MEG.0b013e328353750c

M3 - Article

C2 - 22495399

AN - SCOPUS:84862172190

VL - 24

SP - 739

EP - 746

JO - European Journal of Gastroenterology and Hepatology

JF - European Journal of Gastroenterology and Hepatology

SN - 0954-691X

IS - 7

ER -